Our Team
Executive Team
Dr Alan Walker : Chief Executive Officer
Alan is an experienced CEO with 51 years' experience in big and small pharma and biotech. He spent 28 years in Warner Lambert and 8 years as commercial head of ProStrakan before becoming joint (co founder) CEO Internis until exit. Recently Alan was CEO of Ryboquin the gene engineering company and Nanogenics acquired by Ryboquin.
Prof. W. H. Stimson FRSE: Chief Scientific Officer
Bill is the founder of the Department of Immunology at The University of Strathclyde. He has been involved in eight start-up/spin-out biotech companies. He has been a long -term consultant to five multinational companies including Akzo Nobel, Rhone-Poulenc and Johnson & Johnson. Bill has published 215 scientific papers and 25 patents. He was involved in the use of the first human monoclonal antibodies for cancer therapy.
Allan Watson: Chief Financial Officer
Allan has over 15 years of experience working globally as a CFO for pharmaceutical and med-tech companies with extensive M&A experience as well as having helped deliver a successful IPO. Former CFO roles include those at ProStrakan plc and Optos plc both of which were listed on the main market in London. A pharmacy graduate, he has held a number of finance positions wit companies both within and outside the healthcare sector since qualifying as an accountant.
Board
Peter Bains: Chairman
Peter has over three decades of experience in the pharmaceutical and pharmaceutical and biotech industry including senior strategic and operational roles in a 20+ year career with GSK. He more recently served as CEO of Syngene (where he led a successful IPO and listing) and Sosei Heptares, a Japanese publicly listed company.
Kevin Grainger
Kevin is a serial technology entrepreneur with over 30 years experience. He has successfully established and exited a number of technology businesses. Kevin established the EOS Technology Investment Syndicate in 2014 which is a group of private angel investors focused on early stage science and technology opportunities.
Dr Magnus Nicolson
Magnus has been a CEO, COO and General Manager of Life Science companies in Europe, the US and the Gulf. As COO he listed a company on AMEX. Several small companies he ran have been sold to leading multinationals. He has degrees in Biochemistry, Immunology (MSc &PhD) and an MBA and has taken products all the way from the laboratory to market.
Richard Morgan
Richard has played an active role in the development of over 35 life science companies assisting a number of these with listings on the London Stock Exchange.
Robert Kopple
Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors of several biotechnology companies including MiNA Therapeutics.
Professor David Harrison
David is Professor of Pathology at the University of St. Andrews, with Honorary Chairs in Edinburgh, Glasgow, and Florida. He is also Honorary Consultant Histopathologist at NHS Lothian and Designated Individual with oversight of human tissue in research. His research interests include quantitative pathology and the determination of cell fate after injury.
Chris Brinsmead, CBE
Chris is chairman of the board at Proveca Ltd, Bioscript Ltd and Peakdata AG, he is a Non-executive director of Optibiotox Plc and ILC Therapeutics Ltd and a partner at EOS LLC. He has extensive non executive board experience serving on public, private and charity boards in Life Sciences and other sectors following a thirty year executive career with Astrazeneca.
Appointed a CBE in January 2015 for services to Life Science.
Company Secretary & Finance Director
Hazel Allen
Hazel is a chartered accountant, business performance coach and financial engineer of over 20 years' experience. She has strong commercial and strategic experience including roles at the University of the Highlands and Islands, National Semiconductor Corp & PwC and holds non-executive Director roles in research and commercial organisations.
Advisory Panel
ILC Therapeutics™ is supported by a Scientific Advisory Board with experts and practitioners from industry and academia as well as a number of other highly experienced business professionals.
Scientific Advisory Board
Professor Kathryn Ball – Professor of Biochemistry & Cell Signalling at the Institute of Genetics and Molecular Medicine at the University of Edinburgh
Professor Ted Hupp – Chair of Experimental Cancer Research at the University of Edinburgh
Professor Alex Mullen – Professor of Pharmacy Practice at the University of Strathclyde
Dr Cathy Adamson - Lecturer in Molecular Medicine at the University of St Andrews
Other Advisors
Dr Elisabeth Vokurka – an IP strategy consultant with extensive experience in intellectual property management and supporting SME’s
